Bob Ingratta LifeSciences BC Konrad Sechley Gowlings Peter ...

More documents

Recommendations

Info

New in view of any public disclosure before application filed - Single disclosure Novelty: Invention A + B + C A + B + C A + B + C Prior disclosure A + B A + B + D A + B + C New? Yes Yes No 30
Inventive Step: Not obvious in view of any public disclosure before application filed Multiple disclosures can be considered Invention Disclosure 1 Disclosure 2 Inventive? A + B + C A + B B + D Yes A + B + C A + B B + C Yes Not obvious combine 1 + 2 A + B + C A + B B + C No Obvious combine 1 + 2 31
Page 1 and 2: Bob Ingratta LifeSciences BC Konrad
Page 3 and 4: Managing Intellectual Property Pate
Page 5 and 6: Overview Introduction Bioenergy IP
Page 7 and 8: What is Intellectual Property? Asso
Page 9 and 10: Purpose of the patent system Applic
Page 11 and 12: Cons Expense - National protection
Page 13 and 14: Alternatives to Patenting Trade sec
Page 17 and 18: Eco-Patent Commons “…unleashing
Page 19: Common elements to open access sche
Page 24 and 25: Nature Biotech 24: 643-651 June 200
Page 26 and 27: Increase in US allowance rate - wil
Page 28 and 29: Statutory Subject-Matter CA EP US
Page 32 and 33: Public Disclosure (Prior Art) Made
Page 34 and 35: You have an invention - now what? C
Page 36 and 37: Who is an inventor? Person who “c
Page 38 and 39: Determining inventorship is importa
Page 40 and 41: Where and when to file? What to fil
Page 42 and 43: Provisional, informal filing - prob
Page 44 and 45: Patent Cooperation Treaty PCT appli
Page 46 and 47: Patent Cooperation Treaty Chapter I
Page 48 and 49: Considerations Market size Cost Man
Page 50 and 51: Top tips for reducing costs 1. Dete

Bob Ingratta LifeSciences BC Konrad Sechley Gowlings Peter ...

Create successful ePaper yourself

Delete template?

Save as template?